Hyperhomocysteinemia is related to residual glomerular filtration and folate, but not to methylenetetrahydrofolate-reductase and methionine synthase polymorphisms, in supplemented end-stage renal disease patients undergoing hemodialysis

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 8, 2001, Pages 747-752

  Anwar, W ^a   Gueant J L ^a   Abdelmouttaleb, I ^a   Adjalla, C ^a   Gerard P ^a   Lemoel, G ^a   Erraess, N ^a   Moutabarrek, A ^a   Namour, F ^a  

^a INSERM   (France)

Author keywords

Cystatin C; Folate; Homocysteine; Methionine synthase (MS); Methylenetetrahydrofolate reductase (MTHFR); Renal failture; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENINE; ALBUMIN; C REACTIVE PROTEIN; CREATININE; CYANOCOBALAMIN; CYSTATIN C; CYTOSINE; FOLIC ACID; GUANINE; HOMOCYSTEINE; METHIONINE SYNTHASE; THYMINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLOMERULUS FILTRATION; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

5-METHYLTETRAHYDROFOLATE-HOMOCYSTEINE S-METHYLTRANSFERASE; ADULT; CREATININE; CYSTATINS; FEMALE; FOLIC ACID; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMORPHISM, GENETIC; RENAL DIALYSIS; VITAMIN B 12;

EID: 0034827775     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.124     Document Type: Article

References (33)

1. Hyperhomocysteinemia: An independant risk factor for vascular disease
2. Plasma homocysteine levels and mortality in patients with coronary artery disease
3. The 677C→T mutation in the methylenetetrahydrofolate reductase gene: Associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease
4. 12 and on the risk of premature atherosclerosis
5. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity
6. Homocysteinemia and vascular disease in end-stage renal disease
7. Hyperhomocysteinemia in chronic renal disease
8. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure
9. Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia
10. No net renal extraction of homocysteine in fasting humans
11. Hyperhomocysteinemia: A risk factor for atherosclerosis in chronic uremic patients
12. The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C
13. The blood serum concentration of cystatin C. Implications for the assessment of glomerular filtration rate
14. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
15. Hyperhomocysteinemia as a risk factor for cardiovascular disease in patients undergoing hemodialysis
16. A tale of two homocysteines - And two hemodialysis units
17. Plasma homocysteine in renal failure
18. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis
19. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
20. Homocysteine and folate concentrations in blood from patients treated with hemodialysis
21. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients
22. Influence of 5,10-methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease
23. The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients
24. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects?
25. Sequence analysis of the coding region of human methionine synthase: Relevance to hyperhomocysteinaemia in neural-tube defects and vascular disease
26. The 1298 (A → C) mutation of methylenetetrahydrofolate reductase should be designated to the 1289 position of the gene
27. 12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid
28. Reversal of hyperhomocyst(e)inaemia in chronic renal failure - Is folic or folinic acid the answer?
29. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
30. A common mutation A 1298C in human methylenetetrahydrofolate reductase gene: Association with plasma total homocysteine and folate concentrations
31. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: The result of a meta-analysis
32. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipient with a normal serum creatinine
33. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine